Lv1
10 积分 2022-11-16 加入
[Chinese multidisciplinary expert consensus on combined immunotherapy for hepatocellular carcinoma(2023 version)]
1年前
已完结
The Drug-Dosing Conundrum in Oncology — When Less Is More
1年前
已完结
Improving Dose-Optimization Processes Used in Oncology Drug Development to Minimize Toxicity and Maximize Benefit to Patients
1年前
已完结
Efficacy, safety, and treatment burden of treat-and-extend versus alternative anti-VEGF regimens for nAMD: a systematic review and meta-analysis
1年前
已完结
Teserpaturev/G47Δ: First Approval
2年前
已完结
Reflections on 10 years of the FDA’s breakthrough therapy designation
2年前
已完结
Considering Global Development? Insights from Applications for FDA Breakthrough Therapy and EMA PRIME Designations
2年前
已完结
Assessment of the breakthrough-therapy-designated drugs granted in China: A pooled analysis 2020–2022
2年前
已完结
皖公网安备34019202002308
